Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism.

Acquired hypogonadism is being increasingly recognized in adult men. However, the effects of long term testosterone replacement on bone density and body composition are largely unknown. We investigated 36 adult men with acquired hypogonadism (age, 22-69 yr; median, 58 yr), including 29 men with central hypogonadism and 7 men with primary hypogonadism, and 44 age-matched eugonadal controls. Baseline evaluation included body composition analysis by bioimpedance, determination of site-specific adipose area by dual energy quantitative computed tomography scan (QCT) of the lumbar spine, and measurements of spinal bone mineral density (BMD) using dual energy x-ray absortiometry, spinal trabecular BMD with QCT, and radial BMD with single photon absorptiometry. Percent body fat was significantly greater in the hypogonadal men compared to eugonadal men (mean +/- SEM, 26.4 +/- 1.1% vs. 19.2 +/- 0.8%; P < 0.01). The mean trabecular BMD determined by QCT for the hypogonadal men was 115 +/- 6 mg K2HPO4/cc. Spinal BMD was significantly lower than that in eugonadal controls (1.006 +/- 0.024 vs. 1.109 +/- 0.028 g/cm2; P = 0.02, respectively). Radial BMD was similar in both groups. Testosterone enanthate therapy was initiated in 29 hypogonadal men at a dose of 100 mg/week, and the subjects were evaluated at 6-month intervals for 18 months. During testosterone therapy, the percent body fat decreased 14 +/- 4% (P < 0.001). There was a 13 +/- 4% decrease in subcutaneous fat (P < 0.01) and a 7 +/- 2% increase in lean muscle mass (P = 0.01) during testosterone therapy. Spinal BMD and trabecular BMD increased by 5 +/- 1% (P < 0.001) and 14 +/- 3% (P < 0.001), respectively. Radial BMD did not change. Serum bone-specific alkaline phosphatase and urinary deoxypyridinoline excretion, markers of bone formation and resorption, respectively, decreased significantly over the 18 months (P = 0.003 and P = 0.04, respectively). We conclude that testosterone therapy given to adult men with acquired hypogonadism decreases sc fat and increases lean muscle mass. In addition, testosterone therapy reduces bone remodeling and increases trabecular bone density. The beneficial effects of androgen administration on body composition and bone density may provide additional indications for testosterone therapy in hypogonadal men.

[1]  R. Wolfe,et al.  Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. , 1995, The American journal of physiology.

[2]  H. Broxmeyer,et al.  Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. , 1995, The Journal of clinical investigation.

[3]  A. Klibanski,et al.  Parathyroid Hormone for the Prevention of Bone Loss Induced by Estrogen Deficiency , 1995 .

[4]  O. Arisaka,et al.  Effect of testosterone on bone density and bone metabolism in adolescent male hypogonadism. , 1995, Metabolism: clinical and experimental.

[5]  E. Seeman.  The dilemma of osteoporosis in men. , 1995, The American journal of medicine.

[6]  P. Björntorp,et al.  Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens. , 1995, The Journal of clinical endocrinology and metabolism.

[7]  J. S. Tenover.  Androgen administration to aging men. , 1994, Endocrinology and metabolism clinics of North America.

[8]  A. Abbasi,et al.  Hyposomatomedinemia and hypogonadism in hemiplegic men who live in nursing homes. , 1994, Archives of physical medicine and rehabilitation.

[9]  J. Butler,et al.  A comparison of lateral versus anterior-posterior spine dual energy x-ray absorptiometry for the diagnosis of osteopenia. , 1994, The Journal of clinical endocrinology and metabolism.

[10]  Y. Weisman,et al.  Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH). , 1993, The Journal of clinical endocrinology and metabolism.

[11]  H. Perry,et al.  Effects of Testosterone Replacement Therapy in Old Hypogonadal Males: A Preliminary Study , 1993, Journal of the American Geriatrics Society.

[12]  J. S. Tenover,et al.  Effects of testosterone supplementation in the aging male. , 1992, The Journal of clinical endocrinology and metabolism.

[13]  M. Riggs,et al.  Testosterone Deficiency As a Risk Factor for Hip Fractures in Men: A Case‐Control Study , 1992, The American journal of the medical sciences.

[14]  W. Vale,et al.  Physiologic testosterone levels in normal men suppress high-density lipoprotein cholesterol levels. , 1992, Annals of internal medicine.

[15]  H. Sjöberg,et al.  Testosterone increases serum 1,25-dihydroxyvitamin D and insulin-like growth factor-I in hypogonadal men. , 1992, International journal of andrology.

[16]  R. Poses,et al.  Does Hypogonadism Contribute to the Occurrence of a Minimal Trauma Hip Fracture in Elderly Men? , 1991, Journal of the American Geriatrics Society.

[17]  S. Posen,et al.  Effects of testosterone and venesection on spinal and peripheral bone mineral in six hypogonadal men with hemochromatosis , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  L. Sjöström,et al.  Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. , 1990, Metabolism: clinical and experimental.

[19]  J. Brody,et al.  Hip fracture incidence among the old and very old: a population-based study of 745,435 cases. , 1990, American journal of public health.

[20]  P. Björntorp,et al.  The effects of androgens on the regulation of lipolysis in adipose precursor cells. , 1990, Endocrinology.

[21]  D. Uebelhart,et al.  Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. , 1990, Bone and mineral.

[22]  D. Baylink,et al.  Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. , 1989, The Journal of clinical endocrinology and metabolism.

[23]  D. Schoenfeld,et al.  Elevated serum lipids in hypogonadal men with and without hyperprolactinemia. , 1989, Annals of internal medicine.

[24]  J. Wergedal,et al.  Androgens directly stimulate proliferation of bone cells in vitro. , 1989, Endocrinology.

[25]  C W Hayes,et al.  Body fat distribution measured with CT: correlations in healthy subjects, patients with anorexia nervosa, and patients with Cushing syndrome. , 1989, Radiology.

[26]  W. Crowley,et al.  Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. , 1988, The Journal of clinical endocrinology and metabolism.

[27]  D. Schoenfeld,et al.  Effects of prolactin and estrogen deficiency in amenorrheic bone loss. , 1988, The Journal of clinical endocrinology and metabolism.

[28]  D. Rudman,et al.  Plasma testosterone in nursing home men. , 1988, Journal of clinical epidemiology.

[29]  B. Lawrence Riggs,et al.  Osteoporosis : etiology, diagnosis, and management , 1988 .

[30]  W. Crowley,et al.  Osteoporosis in Men with Idiopathic Hypogonadotropic Hypogonadism , 1987 .

[31]  A. Klibanski,et al.  Osteoporosis in men with hyperprolactinemic hypogonadism. , 1986, Annals of internal medicine.

[32]  H. Genant,et al.  Assessment of metabolic bone diseases by quantitative computed tomography. , 1985, Clinical orthopaedics and related research.

[33]  R M Neer,et al.  Quantitative computed tomography for spinal density measurement. Factors affecting precision. , 1985, Investigative radiology.

[34]  L. Melton,et al.  Risk factors for spinal osteoporosis in men. , 1983, The American journal of medicine.

[35]  N. Niederle,et al.  Testosterone metabolism in human bone. , 1980, Acta endocrinologica.

[36]  J. Cameron,et al.  Measurement of Bone Mineral in vivo: An Improved Method , 1963, Science.